BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24274563)

  • 1. Synthesis and characterization of biotin modified cholesteryl pullulan as a novel anticancer drug carrier.
    Yang W; Wang M; Ma L; Li H; Huang L
    Carbohydr Polym; 2014 Jan; 99():720-7. PubMed ID: 24274563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preliminary evaluation on cholesterol-modified pullulan as a drug nanocarrier.
    Shen S; Li H; Yang W
    Drug Deliv; 2014 Nov; 21(7):501-8. PubMed ID: 24625263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-aggregated nanoparticles from methoxy poly(ethylene glycol)-modified chitosan: synthesis; characterization; aggregation and methotrexate release in vitro.
    Yang X; Zhang Q; Wang Y; Chen H; Zhang H; Gao F; Liu L
    Colloids Surf B Biointerfaces; 2008 Feb; 61(2):125-31. PubMed ID: 17869489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of stearic acid-pullulan nanoparticles.
    Kim IS; Oh IJ
    Arch Pharm Res; 2010 May; 33(5):761-7. PubMed ID: 20512475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy.
    Zhang HZ; Gao FP; Liu LR; Li XM; Zhou ZM; Yang XD; Zhang QQ
    Colloids Surf B Biointerfaces; 2009 Jun; 71(1):19-26. PubMed ID: 19186037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
    Cheng M; Ma D; Zhi K; Liu B; Zhu W
    Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier.
    Tang HB; Li L; Chen H; Zhou ZM; Chen HL; Li XM; Liu LR; Wang YS; Zhang QQ
    Drug Deliv; 2010; 17(7):552-8. PubMed ID: 20550433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of folate-modified pullulan acetate nanoparticles for tumor-targeted drug delivery.
    Zhang HZ; Li XM; Gao FP; Liu LR; Zhou ZM; Zhang QQ
    Drug Deliv; 2010 Jan; 17(1):48-57. PubMed ID: 22747075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier.
    Yang W; Zhang Y; Wang J; Li H; Yang H
    Int J Biol Macromol; 2022 Sep; 216():789-798. PubMed ID: 35914549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin.
    Li L; Gao FP; Tang HB; Bai YG; Li RF; Li XM; Liu LR; Wang YS; Zhang QQ
    Nanotechnology; 2010 Jul; 21(26):265601. PubMed ID: 20522924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pullulan nanoparticle surface charges on HSA complexation and drug release behavior of HSA-bound nanoparticles.
    Tao X; Zhang Q; Ling K; Chen Y; Yang W; Gao F; Shi G
    PLoS One; 2012; 7(11):e49304. PubMed ID: 23166632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
    Yu JM; Li YJ; Qiu LY; Jin Y
    J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New method and characterization of self-assembled gelatin-oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction.
    Park C; Vo CL; Kang T; Oh E; Lee BJ
    Eur J Pharm Biopharm; 2015 Jan; 89():365-73. PubMed ID: 25536111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of doxorubicin to liver used a novel biotinylated β-cyclodextrin grafted pullulan nanocarrier.
    Yang W; Xue Y; Cui X; Tang H; Li H
    Colloids Surf B Biointerfaces; 2022 Dec; 220():112934. PubMed ID: 36265313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pullulan-based nanoparticles as carriers for transmucosal protein delivery.
    Dionísio M; Cordeiro C; Remuñán-López C; Seijo B; Rosa da Costa AM; Grenha A
    Eur J Pharm Sci; 2013 Sep; 50(1):102-13. PubMed ID: 23624352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular uptake mechanism and intracellular fate of hydrophobically modified pullulan nanoparticles.
    Jiang L; Li X; Liu L; Zhang Q
    Int J Nanomedicine; 2013; 8():1825-34. PubMed ID: 23674894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ester anhydride)/mPEG amphiphilic block co-polymer nanoparticles as delivery devices for paclitaxel.
    Liang Y; Xiao L; Li Y; Zhai Y; Xie C; Deng L; Dong A
    J Biomater Sci Polym Ed; 2011; 22(4-6):701-15. PubMed ID: 20566053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
    Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
    Garg A; Singh S
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, characterization, release kinetics and toxicity profile of drug-loaded starch nanoparticles.
    El-Naggar ME; El-Rafie MH; El-sheikh MA; El-Feky GS; Hebeish A
    Int J Biol Macromol; 2015 Nov; 81():718-29. PubMed ID: 26358550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.